<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620369</url>
  </required_header>
  <id_info>
    <org_study_id>MC19C1</org_study_id>
    <secondary_id>NCI-2020-08287</secondary_id>
    <secondary_id>MC19C1</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04620369</nct_id>
  </id_info>
  <brief_title>Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>Rose Geranium in Sesame Oil Nasal Spray as an Agent to Improve Symptoms of Nasal Vestibulitis: A Phase III Double Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares rose geranium in sesame oil nasal spray to isotonic nasal&#xD;
      saline in improving symptoms of nasal vestibulitis in cancer patients receiving chemotherapy.&#xD;
      Nasal (nose) symptoms (dryness, discomfort, bleeding, scabbing or sores) due to inflammation,&#xD;
      termed nasal vestibulitis, is reported as a side effect of cancer-directed therapy. Rose&#xD;
      geranium in sesame oil nasal spray may work better than isotonic nasal saline in improving&#xD;
      symptoms of nasal vestibulitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the ability of rose geranium in sesame oil nasal spray to alleviate nasal&#xD;
      vestibulitis in patients undergoing systemic, antineoplastic therapy when compared with&#xD;
      isotonic nasal saline.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To assess toxicities related to rose geranium in sesame oil nasal spray in this study&#xD;
      situation.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril&#xD;
      twice daily (BID) on days 1-14 in the absence of unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in&#xD;
      the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in&#xD;
      sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable&#xD;
      toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>At 2 weeks after initiating the nasal spray</time_frame>
    <description>Response is determined from a patient global impression of change scale and is defined as a patient reporting that the nasal symptom that was most prominent prior to starting the study has been moderately better or very much better 2 weeks after initiating the nasal spray. The number and percentage of patients experiencing a response 2 weeks after initiating the nasal spray will be estimated within each randomized arm and the corresponding two-sided 95% exact (Clopper-Pearson) confidence interval provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>At 2 weeks after initiating the nasal spray</time_frame>
    <description>Response is determined from a patient global impression of change scale and is defined as a patient reporting that the nasal symptom that was most prominent prior to starting the study has been moderately better or very much better 2 weeks after initiating the nasal spray. A between-arm comparison of the proportion of patients experiencing a response 2 weeks after initiating the nasal spray will be made using the Fisher's exact test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of most prominent nasal symptom indicated at baseline</measure>
    <time_frame>Up to 2 weeks after initiating the nasal spray</time_frame>
    <description>For the most prominent nasal symptom indicated at baseline, patients will record the severity on an ordinal scale of 1=mild, 2=moderate, 3=severe, and 4=very severe. Two weeks after initiating the nasal spray the patients will record the severity of the most prominent nasal symptom as 0=none, 1=mild, 2=moderate, 3=severe, and 4=very severe. A shift table will be created to descriptively display the number of patients who record a 1, 2, 3, or 4 at baseline and the shift two-weeks after initiating the nasal spray. In addition, the within-patient change in severity of the most prominent nasal symptom will be calculated 2 weeks after initiating the nasal spray and summarized descriptively within each arm. The Wilcoxon rank-sum test will be performed, and the methods of Hodges and Lehmann will be applied to compute a point estimate and confidence interval for the difference in medians between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal symptom analysis of dryness, pain, bleeding, and scabbing</measure>
    <time_frame>Up to 2 weeks after initiating the nasal spray</time_frame>
    <description>Each nasal symptom (dryness, pain, bleeding, and scabbing) will be descriptively summarized, tabulated, and plotted according to arm at baseline. Shift tables will also be generated to descriptively display the number of patients who record a 1, 2, 3, or 4 at baseline after initiating the nasal spray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal symptom analysis of dryness, pain, bleeding, and scabbing</measure>
    <time_frame>Up to 2 weeks after initiating the nasal spray</time_frame>
    <description>Each nasal symptom (dryness, pain, bleeding, and scabbing) will be descriptively summarized, tabulated, and plotted according to arm at 1 and 2 weeks post-baseline. Shift tables will also be generated to descriptively display the number of patients who record a 1, 2, 3, or 4 at baseline and the shift one- and two-weeks after initiating the nasal spray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal symptom analysis of dryness, pain, bleeding, and scabbing</measure>
    <time_frame>Up to 2 weeks after initiating the nasal spray</time_frame>
    <description>Each nasal symptom (dryness, pain, bleeding, and scabbing) will be descriptively summarized, tabulated, and plotted. Patient will be grouped according to baseline severity for each symptom and summarize changes over time and according to arm. Shift tables will also be generated to descriptively display the number of patients who record a 1, 2, 3, or 4 at baseline and the shift one- and two-weeks after initiating the nasal spray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 2 weeks after initiating the nasal spray</time_frame>
    <description>The constellation of AEs as scored using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 will be summarized within arms by reporting the number and percentage of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 2 weeks after initiating the nasal spray</time_frame>
    <description>Evaluate the AE profiles associated with each arm, the maximum grade for each type of AE will be recorded for each patient and frequency tables will be reviewed to determine overall patterns and compared between arms using Wilcoxon tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Nasal Vestibulitis</condition>
  <arm_group>
    <arm_group_label>Arm A (rose geranium in sesame oil nasal spray)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (isotonic nasal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Instill isotonic nasal saline intranasally</description>
    <arm_group_label>Arm B (isotonic nasal saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (rose geranium in sesame oil nasal spray)</arm_group_label>
    <arm_group_label>Arm B (isotonic nasal saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rose Geranium in Sesame Oil Nasal Spray</intervention_name>
    <description>Instill intranasally</description>
    <arm_group_label>Arm A (rose geranium in sesame oil nasal spray)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  REGISTRATION-INCLUSION CRITERIA&#xD;
&#xD;
          -  Be diagnosed with cancer and receiving chemotherapy&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Willingness to complete questionnaires&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2&#xD;
&#xD;
          -  One or more of the following nasal symptoms for which the patient reports they would&#xD;
             appreciate treatment. Symptoms must have started after the initiation of systemic,&#xD;
             antineoplastic therapies, be attributed to the systemic, antineoplastic therapies, and&#xD;
             symptoms must be reported as being moderate (corresponding to a score of 2) or worse&#xD;
             on a scale from mild (1) to very severe (4) on at least one of the items below.&#xD;
&#xD;
               -  Dryness&#xD;
&#xD;
               -  Discomfort/pain&#xD;
&#xD;
               -  Bleeding&#xD;
&#xD;
               -  Scabbing&#xD;
&#xD;
               -  Sores&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  REGISTRATION-EXCLUSION CRITERIA&#xD;
&#xD;
          -  Predisposition to epistaxis prior to the initiation of cancer-directed therapy (more&#xD;
             than once a month over the previous year)&#xD;
&#xD;
          -  Planned initiation or continuation of any topical nasal treatment other than the&#xD;
             studied nasal spray,(such as nasal steroids, Ayr nasal gel, Neosporin ointment or&#xD;
             nasal administration of petroleum jelly). Taking Imitrex for migraines is acceptable&#xD;
&#xD;
          -  Previous exposure to rose geranium in sesame oil nasal spray&#xD;
&#xD;
          -  Concurrent upper respiratory tract infection&#xD;
&#xD;
          -  History of allergic or other adverse reactions to sesame oil or essential rose&#xD;
             geranium oil&#xD;
&#xD;
          -  Any other reason that the study clinician or investigator feels precludes safe or&#xD;
             appropriate inclusion in this study&#xD;
&#xD;
          -  Vulnerable populations: pregnant women, prisoners, mentally handicapped&#xD;
&#xD;
          -  RE-REGISTRATION&#xD;
&#xD;
          -  The patient will be un-blinded and determined to have been on the saline arm, when&#xD;
             initially randomized&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L Loprinzi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Essentia Health St. Joseph's Medical Center</name>
      <address>
        <city>Brainerd</city>
        <state>Minnesota</state>
        <zip>56401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Deer River</name>
      <address>
        <city>Deer River</city>
        <state>Minnesota</state>
        <zip>56636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health St. Mary's Detroit Lakes</name>
      <address>
        <city>Detroit Lakes</city>
        <state>Minnesota</state>
        <zip>56501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Cancer Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Ely Clinic</name>
      <address>
        <city>Ely</city>
        <state>Minnesota</state>
        <zip>55731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bred Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Fosston</name>
      <address>
        <city>Fosston</city>
        <state>Minnesota</state>
        <zip>56542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Itasca Clinic &amp; Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Minnesota</state>
        <zip>55744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastas Provatas, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Anastas Provatas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Hibbing</name>
      <address>
        <city>Hibbing</city>
        <state>Minnesota</state>
        <zip>55746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview Range Medical Center</name>
      <address>
        <city>Hibbing</city>
        <state>Minnesota</state>
        <zip>55746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anasta Provatas, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Anastas Provatas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health International Falls Clinic</name>
      <address>
        <city>International Falls</city>
        <state>Minnesota</state>
        <zip>56649</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MMCORC Monticello Cancer Center</name>
      <address>
        <city>Monticello</city>
        <state>Minnesota</state>
        <zip>55362</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Anderson, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Dan Anderson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Park Rapids</name>
      <address>
        <city>Park Rapids</city>
        <state>Minnesota</state>
        <zip>56470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview Northland Medical Center</name>
      <address>
        <city>Princeton</city>
        <state>Minnesota</state>
        <zip>55731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastas Provatas, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Anastas Provatas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Charles L. Loprinzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Sandstone</name>
      <address>
        <city>Sandstone</city>
        <state>Minnesota</state>
        <zip>55072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Thief River Falls Medical Center</name>
      <address>
        <city>Thief River Falls</city>
        <state>Minnesota</state>
        <zip>56701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Panwalkar, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Amit Panwalkar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Health Virginia</name>
      <address>
        <city>Virginia</city>
        <state>Minnesota</state>
        <zip>55792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bret Friday, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bret Friday, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Worthington</name>
      <address>
        <city>Worthington</city>
        <state>Minnesota</state>
        <zip>56187</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Bleeker, M.D.</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Bleeker, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

